Skip to main content
OpenTrials

Clinical trial condition

ER+ Breast Cancer

Explore clinical trials studying ER+ Breast Cancer. Study availability and eligibility vary by location and protocol.

23 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

ER+ Breast Cancer trial results

Active, not recruiting

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

NCT06590857

Conditions
Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Breast Diseases, +13 more
Locations
  • Research Facility Phoenix, Arizona, United States
  • Research Facility Irvine, California, United States
  • Research Facility San Diego, California, United States
  • Research Facility Santa Monica, California, United States
View all 31 locations
View Trial Details
Active, not recruiting

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

NCT04360941

Conditions
Breast Diseases, Breast Neoplasms, ER+ Breast Cancer, +10 more
Locations
  • The Christie NHS Foundation Trust Manchester, Greater Manchester, United Kingdom
  • Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust Cambridge, United Kingdom
  • Beatson West of Scotland Cancer Centre Glasgow, United Kingdom
  • Hope Clinical Trials Cancer Centre Leicester, United Kingdom
View Trial Details
Active, not recruiting

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

NCT04920708

Conditions
Advanced Breast Cancer, Breast Diseases, Breast Neoplasms, +6 more
Locations
  • Addenbrookes Hospital Cambridge, Cambridgeshire, United Kingdom
  • Royal Cornwall Hospital Truro, Cornwall, United Kingdom
  • Mount Vernon Cancer Centre London, Surrey, United Kingdom
  • Velindre Cancer Centre Cardiff, Wales, United Kingdom
View all 13 locations
View Trial Details
Active, not recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NCT03983954

Conditions
Adenocarcinoma, Adenocarcinoma Of Esophagus, Adenoma, +79 more
Locations
  • Shalby Hospital Ahmedabad, Gujarat, India
  • National Cancer Institute Jhajjar, Haryana, India
  • All India Institute of Medical Sciences New Delhi, India
  • PMCH (Pacific Medical College & Hospital) Udaipur, Rajasthan, India
View Trial Details
Completed

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

NCT00828854

Conditions
Breast Diseases, Breast Neoplasms, ER+ Breast Cancer, +4 more
Locations
  • St. Vincent's University Hospital Dublin, Ireland
  • The University of Birmingham Birmingham, United Kingdom
  • Velindre Hospital - Whitchurch Cardiff, United Kingdom
  • Whiston Hospital; Clatterbridge Centre for Oncology Liverpool, United Kingdom
View Trial Details
Completed

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

NCT00676663

Conditions
Animal Diseases, Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, +9 more
Locations
  • California Cancer Care Greenbrae, California, United States
  • Moores UCSD Cancer Center La Jolla, California, United States
  • Scripps Health La Jolla, California, United States
  • University of Colorado Aurora, Colorado, United States
View all 38 locations
View Trial Details

Related conditions